AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18981033 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 16360311 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot zuclopenthixol
Number of subjects: 46
Study 16360311 — intervention group
Group type: COMPARATOR
Intervention: Oral zuclopenthixol
Number of subjects: 46
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-17 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-14 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-14 (2.0 microg/kg/h iv over 120 min)
Number of subjects: 6
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-17
Number of subjects: 6
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: CST-14
Number of subjects: 6
Study 15336231 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-14
Number of subjects: 6
Study 11910616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (16, 32, or 64 mg daily for 14 days)
Number of subjects: 27
Study 11910616 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen (continuous for 28-day cycle)
Number of subjects: 27
Study 11910616 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary progesterone levels
Number of subjects: 27
Study 9295821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb)
Number of subjects: 14
Study 8116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (162 mg)
Number of subjects: 15
Study 8116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (18 mg)
Number of subjects: 15
Study 8116856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lysine acetylsalicylate and furosemide
Number of subjects: 15
Study 8116856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31764785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day, orally)
Number of subjects: 423
Study 31764785 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (Enoxaparin, 4000 anti-Xa IU/day, subcutaneous injection)
Number of subjects: 423
Study 31764785 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticoagulant)
Number of subjects: 423
Study 28499376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based childbirth preparation course (MIL)
Number of subjects: 30
Study 28499376 — intervention group
Group type: COMPARATOR
Intervention: Standard childbirth preparation course (Control)
Number of subjects: 30
Study 25398453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 121
Study 25398453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 21985749 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 13
Study 21985749 — intervention group
Group type: COMPARATOR
Intervention: Placebo Inspiratory Muscle Training (P-IMT)
Number of subjects: 13
Study 21535997 — intervention group
Group type: EXPERIMENTAL
Intervention: 7,000 lux fluorescent bright white light
Number of subjects: 27
Study 21535997 — intervention group
Group type: COMPARATOR
Intervention: 70 lux dim red (placebo) light
Number of subjects: 27
Study 18270369 — intervention group
Group type: EXPERIMENTAL
Intervention: High folate intake
Number of subjects: 26556
Study 18270369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6, vitamin B12, and methionine intakes
Number of subjects: 26556
Study 16480742 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Task (PVSAT) in CIS patients
Number of subjects: 36
Study 16480742 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Visual Serial Addition Task (PVSAT) in CDMS patients
Number of subjects: 36
Study 16480742 — intervention group
Group type: COMPARATOR
Intervention: Paced Visual Serial Addition Task (PVSAT) in healthy controls
Number of subjects: 36
Study 16480742 — intervention group
Group type: COMPARATOR
Intervention: Paced Auditory Serial Addition Task (PASAT)
Number of subjects: 36
Study 12911658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecabet sodium 1 g b.i.d and cimetidine 400 mg b.i.d.
Number of subjects: 200
Study 12911658 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.i.d. alone
Number of subjects: 200
Study 11164441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 2749
Study 11164441 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic goal of total cholesterol < 5.0 mmol/l
Number of subjects: 2749
Study 11164441 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic goal of total cholesterol < 4.5 mmol/l
Number of subjects: 2749
Study 9280037 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran fibre supplement
Number of subjects: 0
Study 9280037 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8243794 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day tenoxicam
Number of subjects: 36
Study 8243794 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/day diclofenac sodium
Number of subjects: 36
Study 8243794 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori colonization
Number of subjects: 36
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐mode ultrasound
Number of subjects: 75
Study 3511125 — intervention group
Group type: COMPARATOR
Intervention: Waters view radiographs
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough and rhinorrhea symptoms
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Copious rhinorrhea
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Purulent rhinorrhea
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear abnormalities
Number of subjects: 75
Study 3511125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometry findings
Number of subjects: 75
Study 31515531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch-repair-deficient strain
Number of subjects: 100
Study 31515531 — intervention group
Group type: COMPARATOR
Intervention: Mismatch-repair-proficient strain
Number of subjects: 100
Study 29305240 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF+Arg/Citr (Arg, 0.2 g/kg/day; Citr, 0.1 g/kg/day) with daily chloroquine (50 mg)
Number of subjects: 29
Study 29305240 — intervention group
Group type: COMPARATOR
Intervention: Base RUSF with weekly chloroquine (150 mg)
Number of subjects: 29
Study 27357093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages (4 servings/d)
Number of subjects: 24
Study 27357093 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-sweetened beverages (4 servings/d)
Number of subjects: 24
Study 27357093 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverages (4 servings/d)
Number of subjects: 24
Study 27357093 — intervention group
Group type: COMPARATOR
Intervention: Standardized diet ad libitum
Number of subjects: 24
Study 24886344 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional nurse-led mental health promotion intervention for six months
Number of subjects: 142
Study 22435370 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN727 (50 mg)
Number of subjects: 132
Study 22435370 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN727 (100 mg)
Number of subjects: 132
Study 22435370 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN727 (150 mg)
Number of subjects: 132
Study 22435370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 20521869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with latex extract
Number of subjects: 21
Study 20521869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17239657 — intervention group
Group type: EXPERIMENTAL
Intervention: sumanirole 0.5mg
Number of subjects: 270
Study 17239657 — intervention group
Group type: EXPERIMENTAL
Intervention: sumanirole 1.0mg
Number of subjects: 270
Study 17239657 — intervention group
Group type: EXPERIMENTAL
Intervention: sumanirole 2.0mg
Number of subjects: 270
Study 17239657 — intervention group
Group type: EXPERIMENTAL
Intervention: sumanirole 4.0mg
Number of subjects: 270
Study 17239657 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 270
Study 17239657 — intervention group
Group type: EXPERIMENTAL
Intervention: sumanirole (all doses)
Number of subjects: 270
Study 14971965 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g Cr + 18 g dextrose taken 4 times per day for 5 days
Number of subjects: 10
Study 14971965 — intervention group
Group type: COMPARATOR
Intervention: 18 g dextrose as placebo (PL)
Number of subjects: 10
Study 11354858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft
Number of subjects: 65
Study 11354858 — intervention group
Group type: COMPARATOR
Intervention: Hamstring (HS) autograft
Number of subjects: 65
Study 11354858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PT and HS groups
Number of subjects: 65
Study 9389813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate, 12.5 mg, and T undecanoate, 80 mg, administered orally twice daily for 16 weeks
Number of subjects: 8
Study 7697688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated (EC) naproxen tablets 500 mg twice daily
Number of subjects: 24
Study 7697688 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen tablets 500 mg twice daily
Number of subjects: 24
Study 2959197 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg i.v. + Rifampin 600 mg orally
Number of subjects: 10
Study 2959197 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg i.v. + Rifampin 300 mg i.v.
Number of subjects: 10
Study 2959197 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin-rifampin combination
Number of subjects: 10
Study 2959197 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 10
Study 30175648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 8 weekly sessions of 45-60 minutes each.
Number of subjects: 74
Study 30175648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT).
Number of subjects: 74
Study 27302208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplementation (2000 IU/D)
Number of subjects: 120
Study 27302208 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly vitamin D3 supplementation (40,000 IU/month)
Number of subjects: 120
Study 27302208 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 120
Study 27022005 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-imagination (SI)
Number of subjects: 20
Study 27022005 — intervention group
Group type: COMPARATOR
Intervention: Semantic processing
Number of subjects: 20
Study 27022005 — intervention group
Group type: COMPARATOR
Intervention: Self-referential strategies
Number of subjects: 20
Study 24495415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 40
Study 24495415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dissection tonsillectomy
Number of subjects: 40
Study 22381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake (quartiles)
Number of subjects: 92
Study 22381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine intake (quartiles)
Number of subjects: 92
Study 22381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake (quartiles)
Number of subjects: 92
Study 22381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine intake (quartiles)
Number of subjects: 92
Study 19515415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 50 mug
Number of subjects: 332
Study 19515415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 mug
Number of subjects: 332
Study 19515415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 300 mug
Number of subjects: 332
Study 19515415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 600 mug
Number of subjects: 332
Study 19515415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 332
Study 19515415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 17475412 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogenic oral contraceptive (30 microg ethinyl estradiol combined with 3 mg drospirenone) for 3 months
Number of subjects: 21
Study 17475412 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 21
Study 15675932 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal S(+)‐ketamine 1 mg.kg(‐1) (group K)
Number of subjects: 40
Study 15675932 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal S(+)‐ketamine 0.5 mg.kg(‐1) plus neostigmine 10 microg.kg(‐1) (group KN)
Number of subjects: 40
Study 11860044 — intervention group
Group type: EXPERIMENTAL
Intervention: General enhancement classroom program
Number of subjects: 1500
Study 11860044 — intervention group
Group type: EXPERIMENTAL
Intervention: General enhancement plus small-group peer-skills training
Number of subjects: 1500
Study 11860044 — intervention group
Group type: EXPERIMENTAL
Intervention: General enhancement plus small-group peer-skills training plus family intervention
Number of subjects: 1500
Study 11860044 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 1500
Study 10030482 — intervention group
Group type: COMPARATOR
Intervention: Standard didactic presentation training for staff at four agencies
Number of subjects: 15425
Study 10030482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training paired with standard didactic presentation for staff at five agencies
Number of subjects: 15425
Study 10030482 — intervention group
Group type: COMPARATOR
Intervention: Family therapy services
Number of subjects: 15425
Study 10030482 — intervention group
Group type: COMPARATOR
Intervention: Family support services
Number of subjects: 15425
Study 10030482 — intervention group
Group type: COMPARATOR
Intervention: Educational or support programs for families
Number of subjects: 15425
Study 7673533 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention (home-based parent training and school-based social skills training)
Number of subjects: 0
Study 7673533 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 1692944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin (2.0 mg t.i.d.)
Number of subjects: 16
Study 1692944 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg t.i.d.)
Number of subjects: 16
Study 6153847 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine monohydrochloride 1000 mg daily
Number of subjects: 65
Study 6153847 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65
Study 31471421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1
Study 31471421 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 1
Study 27898479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressing group (n = 30)
Number of subjects: 64
Study 27898479 — intervention group
Group type: COMPARATOR
Intervention: Nonpressing group (n = 30)
Number of subjects: 64
Study 25452139 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 125 mcg
Number of subjects: 421
Study 25452139 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 250 mcg
Number of subjects: 421
Study 25452139 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 31.25 mcg
Number of subjects: 421
Study 25452139 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC 62.5 mcg
Number of subjects: 421
Study 25452139 — intervention group
Group type: COMPARATOR
Intervention: FF
Number of subjects: 421
Study 23788218 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 148
Study 23788218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 23788218 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 148
Study 21849168 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted planar reaching (gravity compensated)
Number of subjects: 62
Study 21849168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined planar with vertical robot-assisted reaching
Number of subjects: 62
Study 21849168 — intervention group
Group type: COMPARATOR
Intervention: Intensive conventional arm exercise program
Number of subjects: 62
Study 21849168 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar robot-assisted exercise (for participants with greater motor impairment)
Number of subjects: 62
Study 18956153 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental zinc daily for 6 months)
Number of subjects: 90
Study 18956153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17960961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 or 30 mg/day)
Number of subjects: 161
Study 17960961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 161
Study 17960961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 14733999 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA between 1.0 and 2.99 ng/ml with f/t PSA ratio < or =20%; 249 biopsies indicated, 159 performed (acceptance 63.9%)
Number of subjects: 1097
Study 14733999 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA between 3.0 and 3.99 ng/ml; 72 men recommended for biopsy, 56 performed (77.8%)
Number of subjects: 1097
Study 14733999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers detected in the study
Number of subjects: 1097
Study 11524048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 50
Study 11524048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 50
Study 11524048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9642018 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantically complex verbs (e.g., run)
Number of subjects: 8
Study 9642018 — intervention group
Group type: COMPARATOR
Intervention: Semantically simpler verbs (e.g., go)
Number of subjects: 8
Study 7916883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation of sulfur dioxide (SO2)-air
Number of subjects: 37
Study 7916883 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation of cold air
Number of subjects: 37
Study 2379442 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of glucose daily with no phosphorus
Number of subjects: 16
Study 2379442 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g of glucose with 7.5 mmol of phosphate daily
Number of subjects: 16
Study 2379442 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g of glucose with 15 mmol of phosphate daily
Number of subjects: 16
Study 373776 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 700 mg/d
Number of subjects: 40
Study 373776 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin retard (theophylline ethylenediamine oblong tablets) at a dose of 2 X 350 mg/d
Number of subjects: 40
Study 29566588 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSET (Strategic Executive Treatment)
Number of subjects: 43
Study 29566588 — intervention group
Group type: COMPARATOR
Intervention: Cogniplus (computerised repetitive practice training for attention)
Number of subjects: 43
Study 31157708 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesic gel
Number of subjects: 32
Study 31157708 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 32
Study 31157708 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with DOMS
Number of subjects: 32
Study 28494914 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg oral melatonin daily 1 hour before bedtime one day before surgery and for another 5 consecutive days postoperatively
Number of subjects: 139
Study 28494914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 26249300 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (8 sessions of behavioral activation therapy)
Number of subjects: 241
Study 26249300 — intervention group
Group type: COMPARATOR
Intervention: Same-room treatment (8 sessions of behavioral activation therapy)
Number of subjects: 241
Study 22540770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (4 mg/kg/day)
Number of subjects: 140
Study 22540770 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (0.75 mg/kg/day)
Number of subjects: 140
Study 21079147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus oral S-1 (40 mg/m2 twice per day) on days 1 to 14
Number of subjects: 564
Study 21079147 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 6) plus paclitaxel (200 mg/m2) on day 1 every 21 days
Number of subjects: 564
Study 21079147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and S-1
Number of subjects: 564
Study 21079147 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel
Number of subjects: 564
Study 19738339 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (Coartem 20 mg/120 mg)
Number of subjects: 100
Study 19738339 — intervention group
Group type: COMPARATOR
Intervention: Chlorproguanil-Dapsone (Lapdap)
Number of subjects: 100
Study 19738339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 15931654 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (RA)
Number of subjects: 51
Study 15931654 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 51
Study 12851616 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 200 mg/day (F group)
Number of subjects: 37
Study 12851616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day plus folic acid 10 mg/every other day (F+F group)
Number of subjects: 37
Study 10381993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nalmefene
Number of subjects: 176